Roche's IMpower130 Met Co-Primary Endpoints, Lifting ASCO Suspense
Roche said its Phase III IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in the advanced first-line setting for non-squamous lung cancer.
You may also be interested in...
Combination with Abraxane demonstrates an overall survival benefit on top of progression-free survival, but Merck's competing Keytruda has set a high benchmark for first-line metastatic lung cancer.
The lack of significant overall survival benefit in IMpower132 may be related to PD-L1 expression – though the dataset is incomplete – or the higher dose of chemo used in the trial.
Merck came out ahead in the immuno-oncology combination showdown at AACR, with a strong overall survival benefit for Keytruda/chemo in the Phase III KEYNOTE-189 study in first-line NSCLC. The data were seen as practice-changing, but Bristol's CheckMate-227 trial of Opdivo/Yervoy failed to impress in the same way.